JAZZ

Jazz Pharmaceuticals Plc - 10-Q Summary (Q2 2007)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 30, 2007. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on neurology and psychiatry. Key products include Xyrem (sodium oxybate) for narcolepsy and Antizol (fomepizole) for poisonings. The company completed its Initial Public Offering (IPO) on June 6, 2007, raising approximately $97.2 million in net proceeds. In March 2007, the company divested its rights to the product Cystadane.

Key Financial Metrics

Note: Gross margins are not explicitly stated as a percentage in the filing text, but Cost of Product Sales was $1,679k for the quarter and $3,682k for the six months.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 29% for the quarter and 36% for the six months compared to the prior year periods, driven primarily by a 33% increase in Xyrem sales and a 33% increase in Antizol sales.
• Government Settlement Charge: A significant non-recurring charge of $17.5 million was recorded in Q2 2007 related to a civil settlement and plea agreement with the U.S. Department of Justice regarding the marketing of Xyrem. This charge was not present in the prior year.
• Divestiture Gain: The company recorded a $5.1 million gain on the sale of Cystadane rights in the first half of 2007. No comparable gain existed in the prior year.
• Operating Expenses: Research and Development (R&D) expenses increased 22% for the quarter and 19% for the six months, largely due to the Luvox CR license agreement and JZP-6 development. Selling, General, and Administrative (SG&A) expenses increased 33% for the quarter.
• Liquidity: Cash and cash equivalents increased from $78.9 million at year-end 2006 to $148.0 million at June 30, 2007, primarily due to IPO proceeds.

Guidance, Outlook, and Risks

• Luvox CR Launch: The company expects to commence promotion of Luvox CR (fluvoxamine maleate extended release) in the first quarter of 2008, pending FDA approval. The PDUFA action date is December 22, 2007. Significant expenditures are expected in 2007 and 2008 for the launch.
• JZP-6 Development: Two pivotal Phase III trials for JZP-6 (fibromyalgia) are ongoing, with preliminary data expected in the second half of 2008.
• Capital Needs: Management believes current cash, marketable securities, and anticipated revenues will satisfy operations for the next 12 months. However, the company expects to raise additional funds within that period.
• Legal Contingency: The $20.0 million government settlement requires payments from 2007 through 2012. Payments could be accelerated if the company is acquired or generates net income in any year. The company entered a five-year Corporate Integrity Agreement.
• Risk Factors: Key risks include the potential failure of Luvox CR or JZP-6 to receive FDA approval, reliance on single-source suppliers for controlled substances (sodium oxybate), and the impact of generic competition upon the expiration of orphan drug exclusivity for Xyrem (2009/2012).

Investor Verification Checklist

• Settlement Terms: Verify the specific payment schedule and acceleration clauses of the $20 million government settlement.
• Luvox CR Approval: Monitor the FDA's decision on the Luvox CR NDA by the December 22, 2007 PDUFA date.
• Manufacturing Supply: Confirm the status of FDA qualification for the new Xyrem manufacturer (Patheon) and DEA quota allocations for sodium oxybate.
• Cash Burn Rate: Assess the sustainability of the current cash position given the high R&D spend and the upcoming costs for the Luvox CR launch.
• Customer Concentration: Note that Express Scripts accounted for approximately 64-67% of total revenues in the first half of 2007.